Adaptive Biotechnologies (NASDAQ:ADPT) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Adaptive Biotechnologies (NASDAQ:ADPT) from a buy rating to a hold rating in a report published on Saturday.

ADPT has been the subject of several other research reports. JPMorgan Chase & Co. lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. BTIG Research increased their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Guggenheim raised their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Price Performance

ADPT stock opened at $14.85 on Friday. Adaptive Biotechnologies has a fifty-two week low of $6.26 and a fifty-two week high of $20.76. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -37.12 and a beta of 2.19. The business’s fifty day moving average price is $16.80 and its two-hundred day moving average price is $15.83.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter in the previous year, the business posted ($0.23) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 51.0% on a year-over-year basis. Research analysts expect that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insider Transactions at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 53,083 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $15.52, for a total transaction of $823,848.16. Following the sale, the chief executive officer owned 1,934,247 shares of the company’s stock, valued at $30,019,513.44. This trade represents a 2.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kyle Piskel sold 2,145 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $18.46, for a total value of $39,596.70. Following the sale, the chief financial officer owned 216,637 shares in the company, valued at $3,999,119.02. This represents a 0.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 1,144,299 shares of company stock worth $18,705,900. Insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ADPT. Brighton Jones LLC raised its holdings in Adaptive Biotechnologies by 3.1% in the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock valued at $349,000 after buying an additional 700 shares during the last quarter. Bouvel Investment Partners LLC increased its position in Adaptive Biotechnologies by 2.2% in the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after acquiring an additional 904 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Adaptive Biotechnologies by 3.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock valued at $355,000 after acquiring an additional 910 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after purchasing an additional 933 shares during the period. Finally, Captrust Financial Advisors lifted its holdings in shares of Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after purchasing an additional 1,119 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.